Restart Life Sciences Corp (NMLSF) Fair Value & Analysis
Healthcare · US · Market cap $4.4M
Restart Life Sciences Corp
NMLSF · US
Fair value as of: Jul 31, 2026
From 1 valuation models · updated 10 days ago
Fair value updated Jul 31, 2026, revised from $0.0348 to $0.0359 (+3.1%) since Jun 26, 2026. Share price +99.1% over the past month.
Below-average quality, and screening another 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($0.0422). The favourable scenario is already priced in.
- Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.
How to read this chart
60‑month range $0.0101 – $1.23 · fair‑value band $0.0359 – $0.0422 · the $0.0697 price screens above the $0.0359 fair value. Dashed = 300-day average. As of Jul 31, 2026.
Analysis
Restart Life Sciences Corp (NMLSF) currently trades at $0.0697, while our model-based Fair Value estimate is $0.0359, implying the stock looks roughly 48.5% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Trailing-twelve-month revenue stands at $135K. Revenue declined 78.8% year over year. It earns a return on equity of -99.3%. The balance sheet holds a net cash position of $1.4M. Fundamentals as of Jul 31, 2026
Our scenario range runs from $0.0359 (bear case) to $0.0422 (bull case); at $0.0697, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 44% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -48%, NMLSF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 1 models by family
Notify me when NMLSF reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products.
Full company description
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company in Canada. It engages in research and development of psilocybin; and fund food-related research initiative in support of its expanding portfolio of consumer health and wellness products. The company has collaboration with the University of Manitoba's Richardson Centre for food technology and research (RCFTR) to support a series of food-related scientific studies, including the development across various product lines, including BrainQ, BrainBalls, and Holy Crap. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Restart Life Sciences Corp reported revenue of $0 in FY2025 versus $1.5K in FY2021. Reported net income was −$1.4M in FY2025.
NMLSF screens 48% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Restart Life Sciences Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Restart Life Sciences Corp (NMLSF) overvalued or undervalued?
What is the fair value of NMLSF?
What is the quality score of NMLSF?
What is the revenue of Restart Life Sciences Corp (NMLSF)?
What is the net profit margin of NMLSF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Restart Life Sciences Corp and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.